Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema

Bibliography

• Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101(6):1061-70
   PubMed Web of Science ®Google Scholar
• Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64(2):16-20
   PubMed Web of Science ®Google Scholar
• Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145(4):700-6
   PubMed Web of Science ®Google Scholar
• Schartman JP, Coney JM, Hornik JH, et al. Pegaptanib octasodium for the treatment of diabetic macular edema. Expert opin pharmacother 2011;12(8):1317-23
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105(10):1801-15
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61
   PubMed Web of Science ®Google Scholar
• Bhagat N Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806. PMID: 2866759
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. PMID: 8366922
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245-51
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77. e35
   PubMed Web of Science ®Google Scholar
• Agency EM. EPARs for authorised medicinal products for human use: Macugen. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/macugen/macugen.htm [cited 23 January 2009]
   Google Scholar
• Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22(2):143-52
   PubMed Web of Science ®Google Scholar
• Gragoudas ES Adamis AP, Cunningham ET, Feinsod M, et al. Pegatanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol 2012;19(1):4-12
   PubMedGoogle Scholar
• Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501
   PubMedGoogle Scholar
• Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch clin exp ophthalmol 2010;248(7):915-30
   PubMed Web of Science ®Google Scholar
• Peter A, Campochiaro PA, Brown DM, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Opthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-96
   PubMed Web of Science ®Google Scholar
• Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs 2012;72(4):509-23
   PubMed Web of Science ®Google Scholar
• Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013;120:2004-12
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972-9
   PubMed Web of Science ®Google Scholar
• van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31(8):1449-69
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opin pharmacother 2005;6(8):1421-3
   PubMed Web of Science ®Google Scholar
• Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin ther 2006;28(1):36-44
   PubMed Web of Science ®Google Scholar
• Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-8
   PubMed Web of Science ®Google Scholar
• Sultan MB, Zhou D, Loftus J, et al. Macugen Study G. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118(6):1107-18
   PubMed Web of Science ®Google Scholar
• Wolfensberger TJ, Gregor ZJ. Macular edema – rationale for therapy. Dev ophthalmol 2010;47:49-58
   PubMedGoogle Scholar
• Sivaprasad S, Hykin P, Saeed A, et al. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: pan-European experience. Eye(Lond) 2010;24(5):793-8
   Google Scholar
• Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Bougatsos C. Screening for visual impairment in older adults: systematic review to update the 1996 US Preventive Services Task Force Recommendation. U.S. Agency for Healthcare Research and Quality, Rockville, MD; 2009. Report No.: 09-05135-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. PMID: 20722170
   Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology 2014;121(5):1045-53
   PubMed Web of Science ®Google Scholar